Trials / Withdrawn
WithdrawnNCT00620737
Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Castle Creek Biosciences, LLC. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM and placebo when administered to stable restrictive burn scars of an affected joint area.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Autologous Human Fibroblasts (Isolagen TherapyTM) | 1. Collection of skin biopsy. 2. Administration of 2 study injections 3. Performance of various study assessments during clinic visits |
| BIOLOGICAL | Placebo | 1. Collection of skin biopsy. 2. Administration of 2 study injections 3. Performance of various study assessments during clinic visits |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2008-12-01
- First posted
- 2008-02-21
- Last updated
- 2012-02-10
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00620737. Inclusion in this directory is not an endorsement.